- Summary
- Price Reports
- Price History
- Add To Your Stocklist
- View your Stocklist
- Basic Chart
- Interactive Chart
- Headlines
- Company Snapshot
- Summary Reports
- Free Annual Report
- Estimate Snapshot
- Estimate Report
- Mobile Quote
- Real-Time Quote
- Streaming Quote
|
Akela Pharma | Company Snapshot
-
![]()
-
-
-
Vol:
-
Last Trade:
|
AKELA PHARMA INC.
AKELA PHARMA INC. is an integrated drug development company focused on developing therapies for the inhalation market. Its lead product, for the treatment of breakthrough cancer pain, is a Fentanyl formulation delivered using the company's TAIFUN dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD and growth hormone deficiencies.
|
|
| Symbol: |
AKL |
| Exchange(s): |
Toronto Stock Exchange |
| Industry: |
Consumer Products (Biotechnology & Pharmaceuticals) |
| 5-Star Rating: |
 |
|
ANNUAL FINANCIALS
|
|
|
Dec 31, 2008
12 Months
us$
|
Dec 31, 2007
12 Months
us$
|
Dec 31, 2006
12 Months
us$
|
3Yr.
Growth
% Change
|
|
Total Revenue ($000)
|
14,774
|
13,881
|
25,966
|
-30.48
|
|
Earnings before Interest & Tax ($000)
|
-26,946
|
-32,605
|
-22,039
|
N/A
|
|
Profit/Loss ($000)
|
-25,989
|
-32,695
|
-199
|
N/A
|
|
Earnings per Share
|
-1.35
|
-2.79
|
-0.02
|
N/A
|
|
Total Assets ($000)
|
28,457
|
39,141
|
46,603
|
-21.97
|
|
Dividends Per Share
|
0.00
|
0.00
|
0.00
|
|
|
Return on Com. Equity
|
-2,601.72
|
-144.95
|
-0.66
|
|
|
Employees
|
92
|
N/A
|
N/A
|
|
|
|
|
|
Trailing 12 Month Results
|
|
|
12 Months ended
Sep 30, 2009, us$
|
12 Months ended
Sep 30, 2008, us$
|
%Change
|
|
Total Revenue ($000)
|
N/A
|
16,485
|
N/A
|
|
Profit/Loss ($000)
|
N/A
|
-21,267
|
N/A
|
|
Earnings per Share
|
N/A
|
-1.48
|
N/A
|
|
Dividends Per Share
|
0.00
|
0.00
|
|
Number of Shares
|
30,890,338
|
21,615,577
|
|
|
|
|
|
COMPANY INFORMATION
|
|
Report on Business Magazine Top 1000 Ranking
|
| Profit: 0 |
Revenue: 0 |
Assets: 0 |
|
|
|
| Key Personnel |
| CEO: Halvor Jaeger, C.E.O. |
| CFO: Andrew Reiter, C.F.O. |
| |
| Contact Information |
| Address: |
11501 Domain Drive,
Suite 130,
Austin,
TX,
78758 |
Phone: |
512-834-0449 |
| Fax: |
512-834-2105 |
| Web Address: |
www.akelapharma.com |
| E-Mail : |
tbrons@vidacommunication.com |
| Investor Relations: |
Tim Brons, 415-675-7402 |
| |
| Company Type: |
Public |
Company Status: |
Active |
| Auditors: |
Kpmg |
| Transfer Agent: |
Equity Transfer & Trust Company |
| Incorporation:
| Canada |
| |
|
Securities:
|
AKL-T
|
|
| |
|
|
| |
|
|
All information on this site is compiled by CTVglobemedia Publishing Inc. from reliable industry sources. While all efforts are made to ensure the accuracy of the information, CTVglobemedia Publishing Inc. and its related entities assume no liability for incorrect, incomplete, or missing information from this site. Past performance is not necessarily indicative of future performance. Prior to making any investment decision, consult with a qualified investment advisor.
Copyright © 2010 CTVglobemedia Publishing Inc. All rights reserved.
|
|
|
